on Biophytis (EPA:ALBPS)
Biophytis Announces Successful Industrial Transfer of BIO101 Production by Seqens
Paris and Cambridge, June 12, 2024 – Biophytis SA, a clinical-stage biotechnology company focused on age-related diseases, has announced the successful industrial-scale transfer of BIO101 (20-hydroxyecdysone) production by Seqens. Seqens has produced the first GMP-compliant batch at its Villeneuve La Garenne plant.
This batch is set to be used in Biophytis' clinical program for treating respiratory deterioration in Duchenne Muscular Dystrophy (DMD) patients. DMD is a rare genetic disorder leading to severe muscle degeneration. BIO101 shows potential in improving respiratory capacity and quality of life for non-ambulatory patients in advanced stages of DMD.
Biophytis CEO, Stanislas Veillet, stated that this step reinforces their capability to offer unique therapeutic solutions and accelerates the launch of clinical programs. Biophytis is seeking partners and funding to initiate a phase 1-2 clinical trial to evaluate BIO101’s pharmacokinetics, safety, and efficacy in DMD patients.
R. P.Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Biophytis news